España
Estoy tentado de darle un tiro si vuelve a los 4.5, pero creo que me voy a quedar quieto, paso de oncológicas después de la experiencia con THLD. Además, no creéis que puedan hacer un halted, y tenerla así hasta que se investigue lo del pcte fallecido?
ZIOP
NVAX
Vendido otro pak a 7.66
----------------------------------------
NETE - GEVO - VII - PBYI - NVAX (pak simplón)
"Buf, se me está haciendo más largo que un dia sin bolsa"
Yo sigo con mi guerra.......
Paciencia.
Es difícil tenerla, pero trae muy buenos resultados.....
halted? no creo ...
ZIOP
que lentas son las NVAX para lo que estas acostumbrado, eh????
bueno, a ver si al pak simplon le sacas buenas pluses ... :)
ZIOP
Aún no, también las sigo, entraría por donde dijo alguno hoy, a 4.25 +-
"Buf, se me está haciendo más largo que un dia sin bolsa"
Acaban de sacar un sec filing. Lo que se comentaba por aquí esta mañana, que la salud de sus pacientes es muy frágil, y que las muertes son "normales", aunque se van a mirar ese caso concreto de hemorragia intracranial:
“This Phase I study is being conducted in late-stage, recurrent GBM, so these patients are all, unfortunately, medically fragile. The first two patient deaths, which occurred 6.7 months and 3.9 months after treatment, were unrelated to study drug. A third death has just been reported to us and we are collecting and analyzing information in order to properly and timely report it to the FDA. The cause of death is intracranial hemorrhage, which occurred some time after the patient had been discharged from the treating center. This is an isolated case, and there have been no reported related instances of brain hemorrhage in any pervious cohort or prior studies with Ad-RTS-hIL-12 + veledimex. Enrollment remains open in the study, and we will be discussing with our Safety Review Committee the appropriate course of action. For patients who have experienced multiple recurrences, as these patients have, prognoses are particularly poor. Median follow up in the first dose cohort from our study is now 8 months, in a population with an expected overall survival of 3 to 5 months for patients that have failed temozolomide and bevacizumab, or equivalent salvage chemotherapy. For the patients that remain in follow up in this Phase I study, we believe that preliminary overall survival remains encouraging. The Company expects to provide an update once a course of action has been determined.”
http://ir.ziopharm.com/secfiling.cfm?filingID=1193125-16-649074&CIK=1107421
ZIOP